ASND peer analysis
Ascendis Pharma (ASND) against its competitors: price, today's move, 1-year return and market value side by side.
ASND and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BMRN BioMarin | $53.67 | -8.27% | 3.39% | $11.33B |
| CORT Corcept Therapeutics | $80.39 | -0.89% | 11.26% | $8.77B |
| INSM Insmed | $109.43 | -2.80% | -43.66% | $24.70B |
| MBX MBX Biosciences | $54.34 | -2.74% | 149.38% | – |
| NBIX Neurocrine Biosciences | $156.00 | 6.78% | 13.01% | $14.85B |
| RARE Ultragenyx | $16.32 | 1.37% | -53.60% | $1.59B |
| SEPN Septerna | $43.32 | -1.55% | 101.58% | – |
| STOK Stoke Therapeutics | $26.43 | 0.53% | -16.62% | $1.70B |
| UTHR United Therapeutics | $596.83 | -0.32% | 31.60% | $25.68B |
| XERS Xeris Biopharma | $10.13 | -5.42% | 4.33% | $1.95B |
| ASND Ascendis Pharma | $248.82 | -0.98% | 22.14% | $16.53B |
- ASND's peers: BMRN (BioMarin), CORT (Corcept Therapeutics), INSM (Insmed), MBX (MBX Biosciences), NBIX (Neurocrine Biosciences), RARE (Ultragenyx), SEPN (Septerna), STOK (Stoke Therapeutics).
Updated 2026-11-03 00:45 UTC